Class A Medical Device Philippines: How the A/B/C/D Risk Classes Work and What Each Class Has to File

Class A Medical Device in the Philippines: What the A/B/C/D Risk Classes Mean

A Class A medical device in the Philippines is the lowest-risk tier of the ASEAN A/B/C/D scale — typically non-sterile, non-measuring, non-invasive equipment whose failure is unlikely to injure a patient — and it is the tier that generally travels the lighter CMDN notification route rather than full registration. Everything else in this guide is downstream of which letter your product lands on.

The Philippine FDA follows the ASEAN Medical Device Directive framework, so the four classes read as an escalating scale of potential harm:

• Class A — low risk. Broadly, devices that do not enter the body, are not supplied sterile, and do not take a measurement on which treatment depends. Commonly discussed examples include hospital beds and wheelchairs, stethoscopes, non-sterile examination gloves, reusable surgical instruments and general ward furniture. Lightest route, shortest file.
• Class B — low to moderate risk. Devices with short-term contact or a sterile presentation — hypodermic needles, suction equipment, many wound dressings.
• Class C — moderate to high risk. Longer-term contact, active therapeutic function or energy delivery — infusion pumps, ventilators, orthopaedic implants of the less critical kind.
• Class D — high risk. Devices in contact with the heart, central circulation or central nervous system, and those incorporating a medicinal or animal-derived component — heart valves, coronary stents, implantable pacemakers.

Three things importers get wrong here. First, Class A is not “unregulated” — you still need a License to Operate and still need the notification on file before the goods can be sold. Second, the class comes from intended use, not from the object. The same tubing can sit two classes apart depending on where the label says it goes and for how long. Third, the boundary moves: the FDA has been progressively pulling categories out of notification and into full registration with transition windows, so a class or route that applied to a previous filing is a hypothesis, not a plan — check it against the circular in force on the day you file. In-vitro diagnostics use the same four letters but are classified by their own rules; see our IVD certification and registration guide.

This guide is the classification hub for the whole line — every step past the class letter now has its own deep-dive. The filing sequence, in order, is set out in how to register my medical device in the Philippines; the official route and its stages in the Philippines medical device approval process; and what the word certification actually points to in Philippines certification of medical devices.

The Two Layers Behind Every Device Filing — and Where the Risk Class Sits

Philippine medical-device approval runs on two layers, in a fixed order: the establishment layer (a License to Operate, or LTO, held by a Philippine company) and the product layer (a CMDN notification or a CMDR registration, covering one device or one device group). You cannot file at the product layer until the establishment layer exists — that single dependency is what makes most first-time timelines slip.

The full chain, in the order it actually happens:

1. Classify the device into risk class A, B, C or D, under the ASEAN Medical Device Directive (AMDD) rules the Philippines has adopted.
2. Settle the grouping — whether your models file as one application or several. Cost and timeline are set here, before a single form is filled in.
3. Obtain the establishment LTO for the Philippine entity that will import, distribute or manufacture. It is issued by the FDA to the company, not to the product.
4. Build the CSDT dossier and compliant labeling, including legalized foreign documents — quality-system certificate, free-sale proof, authorization letters.
5. File the product application through the FDA's electronic portal — CMDN on the notification track, CMDR on the registration track — under the LTO holder's account.
6. Clear the deficiency letters. Assume there will be at least one; how fast you close them is usually the largest variable you actually control.
7. Receive the authorization — a notification certificate on the CMDN track, a Certificate of Product Registration (CPR) on the registration track.
8. Import and clear customs against a valid license and a valid product authorization, then sustain post-market obligations for as long as you sell.

Steps 1 and 2 are what this guide exists to settle. The rest are treated at full depth elsewhere: the stage-by-stage route in the Philippines medical device approval process, the paperwork sequence in how to register my medical device in the Philippines, and the question of how many applications you end up filing in Philippines medical device grouping requirements.

The four risk classes

Every device sits in one of four classes, and the class is a rule-based conclusion, not a preference:

• Class A — low risk: surgical gloves, bandages, many basic non-invasive consumables.
• Class B — low-moderate risk: hypodermic needles, many patient-monitoring devices.
• Class C — moderate-high risk: many implants and more complex therapeutic equipment.
• Class D — high risk: cardiac implants and life-sustaining devices.

What actually drives the class is a combination of the intended use as stated by the manufacturer, degree of invasiveness, how long the device is in contact with the body, whether it is active (energy-driven) or passive, and — for in-vitro diagnostics — the consequence of a wrong result. Two visually similar products can land in different classes purely because their intended-use statements differ, which is exactly why the intended use in your dossier, on your labels and on your free-sale certificate has to say the same thing.

Get the class wrong and everything downstream is wrong: the track, the dossier depth, the fee bill and the timeline. Note too that which categories are pulled into mandatory registration keeps being adjusted by FDA circulars, with the regulated scope broadly expanding — check current issuances rather than a colleague's memory of an earlier filing. For the two-layer FDA framework across all product categories, see our full FDA product registration guide.

CMDN, CMDR and the CPR: The Two Product Tracks a Class Sends You Down

Three terms get mixed up constantly, so pin them down first:

• CMDN — Certificate of Medical Device Notification. The lighter, notification-based track, historically the route for low-risk Class A devices: you notify the FDA of a device that meets defined requirements and receive a notification certificate.
• CMDR — Certificate of Medical Device Registration. The registration track for higher-risk Classes B, C and D, requiring a full technical dossier and a substantive assessment.
• CPR — Certificate of Product Registration. The authorization document the FDA issues for a registered product. In device conversations, "getting the CPR" and "completing the CMDR" usually describe the same milestone from opposite ends.

The distinction worth holding onto is notification versus registration: one is a declaration against defined requirements, the other is a review of your evidence. Both tracks share the same precondition — the application is filed by a Philippine establishment that already holds a device LTO, and the certificate is issued in that establishment's name, not the foreign manufacturer's. And the boundary between the two is not fixed: the FDA has been progressively moving categories out of notification and into registration, with transitional arrangements. "It was only a notification last time" is not a compliance position. If a buyer or a tender has asked you for the certification of your device and you are not sure which of these three documents they mean, that question is untangled in Philippines certification of medical devices.

Device grouping: one application or twenty

Grouping now has its own full treatment in Philippines medical device grouping requirements — what follows here is the short version you need in order to read the rest of this guide.

Grouping is the most under-estimated decision in Philippine device filings, because fees and review run per application. A catalogue of variants filed as individual singles costs and takes a multiple of what one correctly grouped family does — while a family stretched too wide gets rejected and refiled, which costs more than filing singles would have in the first place.

The ASEAN grouping categories the Philippines works from are generally these:

• Single: one device, supplied as one unit, under one name.
• Family: devices from the same manufacturer sharing the same intended use, same risk class and same core design and manufacturing process, differing only in permitted variations such as size, color, shape or model designation. This is the grouping that saves the most money — and the one most often stretched too far.
• System: devices intended by the manufacturer to be used in combination to achieve a common intended purpose, supplied or packaged together.
• Group / procedure pack: a collection of devices packaged together and sold under a single name for a defined procedure.
• IVD test kit: reagents, calibrators, controls and components packaged together for a defined test.

The working test for a family is easy to state and hard to satisfy: same manufacturer, same intended use, same class, same technology — the differences must be variations, not different devices. A different patient-contact material, a different sterilization method, an added indication, or a second manufacturing site will usually break the family. So build the grouping map before you draft the dossier, write down the justification for every variant you pull into a group, and expect the reviewer to ask for it. This is the most expensive rework in the whole process, because it surfaces late and is fixed by refiling rather than by amendment — and because your grouping decision is simultaneously your fee decision.

Who May Hold the LTO and Bring Devices In

There is no standalone "medical device import license" issued to a foreign manufacturer in the Philippines. What exists is an establishment License to Operate (LTO), issued by the FDA to a Philippine entity, with the authorized activity written on its face — importer, distributor, wholesaler, trader or manufacturer. Two consequences follow, and they surprise most first-time exporters:

• The importer must be a local juridical entity holding a device LTO that covers importation. An overseas manufacturer cannot import into the Philippines in its own name.
• The license's stated activity and scope must actually cover what you are doing. A distributor license does not by itself authorize importation, and a license issued for one line of activity does not automatically extend to another.

On top of the FDA license, the importing entity needs to be accredited with the Bureau of Customs as an importer in order to lodge declarations — an FDA license alone does not get cargo released. At entry, release of a regulated device generally depends on the shipment being covered by a valid establishment license and a valid product authorization; see our guide to Philippine customs clearance and how regulated imports are permitted.

The licensing side is covered in full in its own guide: which documents together do the job of an import license for medical devices in the Philippines, who is eligible to hold them, and how the FDA licence has to pair with customs accreditation before a single carton moves.

Two routes for a foreign manufacturer

• Incorporate and hold your own LTO. Full control of the registration, the pricing and the channel — but slower to start, because incorporation and licensing both precede any product filing.
• Appoint a licensed local authorized representative or importer. A Philippine company that already holds a device LTO files as the licensed party, so entry can begin without incorporating first and product work can run in parallel with your own company set-up. Where the goal is simply to land compliant cargo without owning a local entity, this overlaps heavily with the importer-of-record arrangement — see Importer of Record for how it works and where its limits are.

The trade-off is ownership. On the agent route the LTO and the product authorization both sit in the agent's name, which means the agent legally controls the ability to import your device. If you may later want your own entity to hold the registration, negotiate transfer and exclusivity terms in writing at the start, while you still have leverage. The authorized representative also carries the post-market duties — complaint handling, adverse-event reporting, recall cooperation — so choose on regulatory competence and track record, not on the lowest service fee.

The CSDT Dossier Behind Most Rejections

The CSDT — the ASEAN Common Submission Dossier Template — is the document your application is actually assessed against, and the gap between what it proves and what the label claims is the single most common reason a file comes back. Label content and CSDT content are read against each other, which is why the two are built together. Labeling now has its own dedicated guide, Philippines medical device labeling; the outline kept below is only what you need in order to keep the dossier and the artwork consistent.

Registration-track filings are document-heavy. The core package generally includes:

• Establishment proof: the device LTO, incorporation documents, and the authorized representative's details.
• CSDT technical dossier: the ASEAN Common Submission Dossier Template — device description, intended use, classification rationale, design and manufacturing information, conformity with the essential principles, verification and validation data, risk management, clinical evidence where applicable, plus labeling and instructions for use. This is the document the assessment is actually run against.
• Quality system: the manufacturer's ISO 13485 certificate or equivalent quality-management evidence — valid, and covering the site that actually makes the device.
• Free-sale proof: a Certificate of Free Sale (CFS) or Certificate to Foreign Government from the country of origin, issued by the competent authority, showing the device is legally sold there and covering the models you are filing.
• Authorization chain: a letter of authorization from the legal manufacturer naming your Philippine representative — and where a trading company sits in between, an unbroken chain of authorizations linking manufacturer to trader to representative.
• Legalization: foreign-issued documents generally need notarization plus consular authentication or an Apostille before they are accepted; see how authentication and Apostille work for Philippine filings.

Labeling, in outline

Labeling is assessed inside the dossier, not improvised at the port — the artwork you submit is the artwork you must ship. In substance, Philippine device labeling is expected to carry:

• Identity: the device name and trade name, with enough description to identify what it is.
• Intended use, consistent with the intended use in the dossier and on the free-sale certificate.
• Manufacturer: the legal manufacturer's name and address, and the country of origin.
• The Philippine party: the name and address of the licensed local importer or distributor, with its LTO number. This is the single most common omission on imported stock, because export artwork is printed before the local partner is fixed.
• Traceability: lot or batch number, or serial number where relevant, plus date of manufacture and/or expiry where applicable.
• Status and handling: sterility status and sterilization method where sterile, a single-use indication where single-use, storage and handling conditions, and any warnings, precautions or contraindications.
• The authorization number: the CMDN or CPR number once issued, presented as the FDA requires.
• Instructions for use (IFU): supplied with the device in the manner permitted for that device type. Where electronic IFU is used, follow the conditions currently allowed rather than assuming home-market practice transfers.

Two points repeatedly cost time. Language: English is the working language of Philippine regulation and is what the FDA assesses; additional languages are not a problem in themselves, but every language block must say the same thing, and a claim that appears only in a foreign-language block is still a claim. Symbols: harmonized graphical symbols (the ISO 15223-1 family) are widely relied on, but a symbol substitutes for text only where it is recognized — do not silently replace mandatory text with an icon. On UDI: unique device identification is on the regional regulatory agenda and has been the subject of consultation, but do not assume a US or EU identifier carries over automatically or satisfies a Philippine requirement by itself — treat UDI as a "check the current circular" item, and design artwork so an identifier can be added without re-tooling. The full document package can be coordinated by the Yixing product-access team.

Timelines, Fees and the Rejections That Reset the Clock

Timelines. The FDA works to published processing periods, and those run per the FDA's current schedule — but the elapsed time you experience is driven by four things you decide before you file: the risk class (the notification track moves fastest, Class D is heaviest), the number of applications your grouping produces, the completeness of the CSDT and the legalized foreign documents, and how quickly you answer deficiency letters. A review clock generally pauses while a query sits on your desk, so a slow reply costs you calendar time twice. And the establishment LTO has to be counted in, because the product filing cannot begin without it.

Fees. Official FDA fees apply per the FDA's current schedule and are charged at both layers — the establishment license and each product application — typically scaling with risk class and with the validity period you elect. Because they are charged per application, your grouping decision multiplies or divides the fee bill directly. Budget alongside them for the costs that are not FDA fees at all: consultant or agent service fees, translation, notarization and authentication of foreign documents, any testing or documentation gaps your manufacturer has to close, and label re-artwork and reprinting. We publish no figures here because they move — take the current FDA schedule and a written agent quote.

The rejections that come back again and again

1. Wrong classification. Usually caused by an intended-use statement written for marketing rather than for regulators, pulling the device into a class you did not plan for — or understating it and being corrected mid-review.
2. Grouping that does not hold. Variants bundled as a family but differing in material, sterilization, indication or manufacturing site. Found late, fixed only by refiling.
3. An internally inconsistent dossier. The intended use in the CSDT, on the label, in the IFU and on the free-sale certificate must match. Reviewers cross-read these, and any mismatch becomes a deficiency.
4. A broken authorization chain. The letter of authorization does not trace back to the legal manufacturer named on the ISO 13485 certificate and the CFS, or it has lapsed, or it names an entity that no longer exists.
5. Free-sale certificate problems. Expired, issued by a body that is not the competent authority, not covering the models filed, or not legalized in the accepted form.
6. Non-compliant labels. Missing local importer and LTO number, missing sterility or single-use information, no IFU, or shipped artwork that differs from what was submitted.
7. A license that does not cover the activity. Filing an import-dependent application under an LTO whose stated activity or scope does not include it.

Notice the pattern: almost none of these are scientific objections. They are consistency and paperwork failures — which means they are preventable at desk level before filing, and painfully expensive once they are not.

Most of these seven rejections are avoidable if someone checks your classification and dossier before you file, not after the FDA sends it back. Get your classification checked before you file →

After the CPR: Renewal, Change Control and Post-Market Obligations

The certificate is a license to keep complying, not a finish line. Device post-market oversight is heavier than for ordinary consumer products:

• Validity and renewal. Both the establishment license and the product authorization carry validity periods and must be renewed per the FDA's current schedule, filed ahead of expiry. Letting either lapse is not a paperwork inconvenience: an expired LTO or an expired product authorization means the device can no longer be lawfully imported or sold, and getting back in can be treated as a fresh application.
• Change control. Changes to the manufacturer or manufacturing site, device design, materials, intended use, product name or labeling generally require notification or a new application before the changed product ships. The rule of thumb: if it would have changed the assessment, the FDA has to be told.
• Adverse-event reporting. Serious device-related adverse events, malfunctions and field safety issues must be reported within the timeframes the FDA sets, with records retained.
• Recalls and field corrective actions. You have to be able to execute a recall — which in practice means distribution records good enough to trace a lot to the customers who received it.
• Inspection, sampling and promotion. The FDA inspects licensed establishments and samples marketed devices; device advertising and promotional claims are regulated and may not go beyond the authorized intended use.

All of this lands on the licensed establishment — which, on the agent route, is your local representative rather than you. That is precisely why the agent choice is a compliance decision and not a procurement one: their competence becomes your regulatory record, and their lapse can suspend your product's ability to enter the country.

Summary and Disclaimer

The line, in order: classify (A/B/C/D) → settle the grouping → obtain the establishment LTO → assemble the CSDT, ISO 13485, CFS, authorization chain and compliant labels, all legalized → file CMDN or CMDR → clear deficiencies → receive the notification certificate or the CPR → import against a valid license → maintain renewal, change control and post-market duties. The failures cluster in three places — classification, grouping, and label and document consistency — all of them decided before you file, all of them cheap to fix then and expensive to fix later.

For in-vitro diagnostics the rulebook diverges: the applicable statutes and the ongoing duties are in IVD regulatory affairs Philippines, and the situations that genuinely qualify for a faster queue are in Philippines IVD expedited market access.

This article is general information only and is not legal, regulatory or medical advice. The Philippine FDA's device classification lists, CMDN/CMDR scope, documentary requirements, processing periods, fees and post-market rules are updated by circular and are highly product-specific; what governs your case is the current FDA issuances and professional advice on your actual device. Bring your product description, your intended-use statement, your model list and your quality documents, and start with a free classification, grouping and market-entry assessment from Yixing — the cheapest hour in this process is the one spent before the first filing.